Back to Feed
总结
报道称，特朗普政府曾与16家制药公司达成协议，意在通过“最惠国”(MFN)定价思路以及关税、谈判等手段压低美国处方药成本。但进入今年，多家药企仍在上调部分药品的标价，涨价与“降价协议”目标出现落差。相关分析指出，企业可在既有合同与定价体系下进行调整，且标价上调与患者、医保实际支付之间并不完全等同，政策执行与监管约束仍存不确定性。此事加剧美国控费与产业政策争论，影响患者负担与医保支出预期。
正文
Trump struck deals with 16 drug companies. But they're still raising prices this year NPR US pharma MFN and tariff dynamics: What EU and UK leaders need to know pharmaphorum Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox CSIS | Center for Strategic and International Studies 2026 U.S. drug pricing outlook: 'MFN' is the future BioCentury The Push for Lower US Drug Prices Uses Bad Logic Bloomberg.com
发布时间：